Glaxosmithkline Pharmaceuticals share price today

Glaxosmithkline Pharmaceuticals Ltd's share price was ₹2,531.80 at the close on 4 November 2026. It has been rising for 11 weeks. That is 2.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,122 and ₹3,106, and at that close it sat 42% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Glaxosmithkline Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +56% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: profit up on a year earlier for 10 quarters in a row.

1. Profit up on a year earlier for 10 quarters in a row

   In the June 2026 quarter profit was ₹237 crore, +15.6% on a year earlier.

   Why: Profit rose because the company got better prices and sold more of the higher-value products, which widened the gap between sales and direct product costs.

   Next results: check whether the heavy spending on launches in the first quarter calms down and the profit margin stays near last year's level.

   From the earnings call on 3 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Glaxosmithkline Pharmaceuticals reported revenue of ₹938 crore, up 16.5% from ₹805 crore a year earlier, and a profit of ₹237 crore, up 15.6% from ₹205 crore.

Glaxosmithkline Pharmaceuticals results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Glaxosmithkline Pharmaceuticals' management discussed these results on a call held on 3 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Glaxosmithkline Pharmaceuticals closed at ₹2,531.80 on 4 November 2026, down 2.2% from ₹2,587.90 a year earlier (7 November 2025) and up 54.2% over five years. Its highest weekly close since March 2016 was ₹3,439.60 on 27 June 2025.

Glaxosmithkline Pharmaceuticals share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Glaxosmithkline Pharmaceuticals closed at ₹2,531.80, up 1.5% on the week and down 8.6% on the month. 3 Aug 2026: Glaxosmithkline Pharmaceuticals held its results call for April to June 2026. Management guided: Established GenMed and vaccine businesses planned at 8-10% growth over the 4-5-year 2X horizon, with innovation driving the 13% growth ambition.

Earlier

• Results for April to June 2026: Revenue up 16.5% and profit up 15.6% on a year earlier.
• 29 May 2026: ex-date for a dividend of ₹57 a share.

Glaxosmithkline Pharmaceuticals paid ₹57 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 2.25% at the ₹2,531.80 close on 4 November 2026. The last was a dividend of ₹57 a share, ex-date 29 May 2026.

Glaxosmithkline Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Glaxosmithkline Pharmaceuticals Ltd paid out 93% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 3 August 2026, Glaxosmithkline Pharmaceuticals' management guided: Established GenMed and vaccine businesses planned at 8-10% growth over the 4-5-year 2X horizon, with innovation driving the 13% growth ambition.

“It is safe to say that the worst is behind us.”Bhushan Akshikar, on the call for April to June 2026

What management guided

• Q2 acute-season performance expected to be in line with expectations based on June-July trends.
• Opex and SG&A ratios expected to moderate toward historical levels in following quarters after Q1 concentration.
• Nucala new-patient momentum to be sustained through the next 2 quarters.
• Blenrep launch in the next 2-3 months, most probably Q2 or October to December 2026.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 3 August 2026.

Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units.

Each change stops working if

• : Adult vaccine adoption in institutional and public accounts decelerates or pricing realizations face mandatory discounting.
• : Field force cost inflation outpaces revenue productivity gains or third-party CMO disruptions recur.

The main risks

• : Trelegy Ellipta faces 10-12 generic competitor versions in the Indian market post-patent expiration. ⚠ estimate
• : Imported drug substance and formulation purchases face cost pressures from Indian Rupee depreciation. ⚠ estimate

Our read after the latest results, written 22 August 2026.

When Glaxosmithkline Pharmaceuticals reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 acute-season demand and vaccine availability - check whether July-September trends track the stated in-line expectation and phasing correction.

Glaxosmithkline Pharmaceuticals is on 3 of our India lists: Dividend stocks, Small & mid cap stocks and Pharma stocks.

Glaxosmithkline Pharmaceuticals Ltd earned ₹237 Cr of net profit in the Jun 2026 quarter, +15.6% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹1,036 Cr. Over 10 years profit has grown 10.7% a year on average. That is 25.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹205 Cr.

For the full year, FY26 profit was ₹1,036 Cr (+11.6% on the year before).

Why profit moved: revenue changed +16.5% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +13.0% and revenue +6.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported.

FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Glaxosmithkline Pharmaceuticals Ltd reported ₹938 Cr of revenue in the Jun 2026 quarter, +16.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown 3.0% a year on average. The last full year, FY26, came in at ₹3,822 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Under the Generic-to-Specialty Value Migration framework, Glaxo is pivoting away from commoditized acute formulations toward IP-protected specialty therapies. In Q1 FY27, specialty assets contributed 7.5% of total sales compared to 4.0% in the prior year period, adding approximately 4 percentage points to headline revenue growth. Key contributors include Shingrix, Nucala, Trelegy, and oncology therapies Zejula and Jemperli. The shift enhances gross margins by 150-190 bps and insulates the revenue base from domestic price controls.

The last four reported quarters add to ₹3,954 Cr.

FY26 revenue was ₹3,822 Cr, +1.9% on the year before.

Recent pace: the last four quarters grew +6.3% on average, against 3.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +5.8%, against +6.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +12.4%, against +29.2% a year (rolling over).

FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported.

FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Glaxosmithkline Pharmaceuticals Ltd's operating margin was 31.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 14.0% and 34.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.3 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported.

FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 109% of Glaxosmithkline Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹903 Cr of operating cash against ₹1,036 Cr of profit. After ₹82.0 Cr of spending on assets, ₹821 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 109% of profit came in as cash: the cash cycle got 54 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Glaxosmithkline Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −4 days in FY26, down from 50 days in FY21. It spent ₹167 Cr on assets over the last 3 years. Customers take 26 days to pay, and stock sits for 124 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,822 Cr, each day of that cycle ties up about ₹10.5 Cr, so roughly −₹42.0 Cr is tied up in the business at any time.

FY26: customers took 26 days to pay and stock sat for 124 days, about 4.1 months of sales sitting as stock, for a full cycle of −4 days, shorter than FY21's 50.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 124 days. Customers pay about 26 days after that. Suppliers are paid at 154 days. Together that makes the −4-day cycle.

Spending on assets: ₹167 Cr over the last 3 years, against ₹203 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹33.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Glaxosmithkline Pharmaceuticals Ltd's P/E is 40.7×, near the low end of its own history: it has been lower only 7% of the time. Its usual P/E (the middle reading) is 57.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹63.05.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.